Anteris Technologies Global Corp. (AVR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$9.04+3.67%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · AVR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue global pivotal PARADIGM Trial execution with patient enrollment, regulatory approvals, and reimbursement milestones to support DurAVR commercialization.
Stated as a priority in 2 of last 2 quarters. Revenue increased from $494,000 in 2026-Q1 to $1,009,000 in 2026-Q2, while operating cash outflows decreased from $28.7M to $20.8M, reflecting clinical and regulatory activities supporting the PARADIGM Trial. Management is delivering progress consistent with stated execution milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Q2 marked an important period of execution for Anteris as we advanced the PARADIGM Trial across clinical, regulatory and reimbursement milestones.”
“Q1 2026 reflects strong execution across the PARADIGM Trial, with patient enrolment ongoing in Europe and continued progress on key recruitment activities globally.”
Discontinue additional development contributions under the agreement with v2vmedtech following completion of Stage 1 and during Stage 2 of the development program.
Newly stated in 2026-Q2. Management formally terminated development contributions with v2vmedtech after Stage 1 completion. No direct financial impact figures are provided in the disclosures, so progress is limited to the announcement of termination.
“Notified v2vmedtech of election to discontinue additional development contributions under the Agreement following completion of Stage 1.”
Enter into and commence lease of approximately 181,436 square feet of office and warehouse space to support operations.
Newly stated in 2026-Q2. Management executed a lease agreement for new office and warehouse space in Brooklyn Park, MN. No financial or operational metrics are provided to assess delivery beyond the lease signing.
“Entered into a lease agreement for approximately 181,436 square feet of space in Brooklyn Park, Minnesota.”
Complete capital raises to fund clinical trial execution and advance commercialization of DurAVR THV.
Newly stated in 2026-Q1. Management completed capital raises totaling $320 million in January 2026 to fund the PARADIGM Trial and commercialization efforts. This capital raise is reflected in the financial disclosures and supports ongoing clinical and operational activities.
“Completed aggregate capital raises totalling US$320 million in January 2026 to support execution of the PARADIGM Trial.”
Over the trailing year it converted 0.91x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.